AwesomeCapital

Thursday, January 2, 2025

At least 10 wounded in mass shooting outside Queens nightclub

At least 10 people, mainly teenagers, were injured in a mass shooting outside a nightclub in Queens on Wednesday night, according to sources and the NYPD.

A group of four men fired at least 30 gunshots into a crowd that gathered near the Amazura nightclub in Jamaica just before 11:20 p.m. after a private event at the location, according to cops and the sources.

Six females and four males, ranging in age from 16 to 20, were struck by bullets, NYPD officials said at a Thursday morning press conference.

Police are searching for a light-colored sedan in connection with the shooting.

Scene outside Queens nightclub, where at least 10 were wounded in mass shooting

0 seconds of 55 secondsVolume 66%

None of the victims are in critical condition and all are expected to survive, according to the NYPD.

The victims were transported to area hospitals including Long Island Jewish Hospital and Cohen Children’s Medical Center, according to sources.

A massive police and ambulance response outside Amazura was seen in footage posted to Citizen app.

Photos from the scene show NYPD investigators placing dozens of evidence markers on the street and sidewalk near Amazura.

Amazura has an expansive interior with a capacity for 4,000 people and regularly hosts DJs and live performances.

This is a breaking story. Please check back for updates.

https://nypost.com/2025/01/02/us-news/at-least-10-wounded-in-mass-shooting-outside-queens-nightclub-sources/

Vegas bomber Matthew Livelsberger special forces soldier overseeing drones

Cybertruck bomber Matthew Livelsberger worked in special forces overseeing drone operations and maintenance — as he is pictured for the first time, wearing camouflage and posing with a rifle atop a snowy mountain.

Livelsberger, 37, was last stationed at Camp Panzer Kaserne just southwest of Stuttgart, Germany, where he worked as a remote and autonomous systems manager for the Army.

In that position, Livelsberger was responsible for the “operations, maintenance and integration” of drones in the military.

Livelsberger had been in the Army for at least 19 years — leaving him just one year away from full military retirement benefits.

https://nypost.com/2025/01/02/us-news/vegas-cybertruck-bomber-matthew-livelsberger-revealed-as-special-forces-soldier-overseeing-drones/

FBI rules out role of 3 men, 1 woman allegedly seen planting IEDs near New Orleans attack

The feds ruled out that the ISIS flag-flying terrorist who killed at least 15 people and injured dozens of others on New Orleans’ famed Bourbon Street had help from four people spotted on surveillance footage near the deadly attack Wednesday.

Video surveillance from the French Quarter seemingly showed three men and one woman planting explosives at multiple locations, a federal alert to police departments around the country said soon after the tragic attack.

Federal authorities have since ruled out their involvement in the attack but still suggested that terror suspect Shamsud-Din Jabbar, 42, was not “solely responsible” for the carnage.

At least three IEDs, which were pipe bombs wired with remote detonators, were found at or near the scene, sources said.

https://nypost.com/2025/01/01/us-news/fbi-hunts-terror-cell-in-new-orleans-after-shamsud-din-jabbar-ramming-attack-as-3-men-1-woman-seen-planting-ieds-around-city/

Early cancer diagnoses reach record level in NHS but treatment stuck

The proportion of people with cancer who get a diagnosis in the earliest stages of the disease has risen to a record level in England, but access to treatment remains a barrier to good outcomes.

The results from NHS England come from a study of 13 of the most common cancers – including breast, prostate, and lung cancers – and shows that 58.7% of patients are now being diagnosed at stages 1 or 2, when the cancer is easier to treat.

According to the health service, the record has been reached as a result of a major public awareness drive by the NHS in the last two years and the ramping up of screening tests for common cancers, including the use of mobile scanner units that have been deployed in community settings like shopping centres, stadiums, and supermarket carparks.

The current rate is a 2.7% gain on diagnosis rates seen before the pandemic and is equivalent to an additional 7,000 early diagnoses, said NHS England. However, other figures show that around a third of patients are missing the target of accessing treatment within 62 days of an urgent referral.

That is great news, but the potential impact of those improved diagnosis rates is offset by other problems facing the NHS, including long waiting lists for treatment, which means cancer survival rates in the UK are lagging behind other countries.

A study published last year, for example, found that UK patients were less likely to have chemotherapy or radiotherapy than their counterparts in Australia, Norway, and Canada, and – for those that did have treatment – the wait was significantly longer.

"Lives are saved when cancers are caught early – and following a major drive on early detection in recent years, it's really encouraging to see more people than ever are now being diagnosed at an earlier stage," commented Dame Cally Palmer, National Cancer Director for NHS England.

She acknowledged, however, that there is "still much more to do to save more lives," adding: "We will not let up in our efforts to catch more cancers earlier, where treatment is more likely to be successful."

Efforts will continue to make tests and checks closer to people who need them, continued Dame Cally, and "with new treatments being made available all the time, we will continue to do all we can to get people seen and treated for cancer as early as possible."

https://pharmaphorum.com/news/early-cancer-diagnoses-reach-record-level-nhs

Roche licenses Innovent ADC that could challenge Amgen drug

In a deal valued at up to $1 billion, Roche has licensed rights to a DLL3-directed antibody-drug conjugate (ADC) from China's Innovent Biologics, hoping to bring a competitor to Amgen's recently approved Imdelltra to market.

The deal – which includes an upfront payment of $80 million – grants Roche exclusive global rights to develop, manufacture, and commercialise IBI3009, which has just started clinical testing and has potential as a treatment for small cell lung cancer (SCLC) and other neuroendocrine tumours (NETs).

Amgen brought the first DLL3-targeting drug to market earlier this year after it got US approval for bispecific T-cell engager (BiTE) Imdelltra (tarlatamab) for adults with advanced, extensive-stage SCLC with disease progression on or after platinum-based chemotherapy.

DLL3 is an antigen with low expression in normal tissues, but is significantly overexpressed in certain solid tumours, making it an attractive drug target. Early drug development attempts ran into problems, however, most notably when AbbVie abandoned the development of Rova-T, an anti-DLL3 ADC acquired as part of a $5.8 billion takeover of Stemcentrx, after a phase 3 failure as a post-chemo maintenance therapy in SCLC.

According to Innovent, IBI3009 has shown encouraging anti-tumour activity in multiple animal models, particularly in chemo-resistant cancer types, and has also demonstrated a "favourable safety profile."

Tolerability could be an important differentiator for the drug, as Imdelltra does have safety issues, with its FDA-approved label, including a boxed warning for cytokine release syndrome and neurologic toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS).

Despite that, analysts have suggested that Imdelltra could reach annual sales of $2 billion if it also gets approval for patients with limited-stage SCLC who have not progressed following chemoradiation therapy, a follow-up indication. Amgen priced its drug at $166,500 per patient course.

There's a long way to go before Roche can see if IBI3009 will be a contender that can take on Imdelltra, but it has been cleared for clinical testing in China, the US, and Australia, with the first patient dosed in December. The two companies will work together on the early-stage development of the ADC, after which Roche will take over full development if it passes muster.

Other companies with DLL3 programmes in clinical testing include Boehringer Ingelheim with BI 764532, a CD3xDLL3 bispecific in phase 2 development for advanced or metastatic DLL3-expressing large-cell neuroendocrine carcinoma (NEC) of the lung, and MSD's MK-6070, a DLL3-targeting T-cell engager acquired as part of its takeover of Harpoon Therapeutics, which is in a phase 1/2 study.

https://pharmaphorum.com/news/roche-licenses-innovent-adc-could-challenge-amgen-drug